Quarterly results
2018 Second Quarter and R&D update
We announced our second quarter 2018 results on Wednesday 25 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our performance and financial outlook, and Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update.
Highlights
Downloads
- Q2 2018 results and R&D update announcement PDF - 1.0MB
- Q2 2018 slides - Emma Walmsley PDF - 495.7KB
- Q2 2018 slides - Simon Dingemans PDF - 131.7KB
- R&D update slides - Hal Barron PDF - 1.9MB
- Q2 2018 results transcript - Part 1 PDF - 188.4KB
- Q2 2018 results transcript - Part 2 PDF - 242.3KB
- Q2 2018 results infographic PDF - 556.7KB
- Q2 2018 US dollar translation PDF - 131.6KB
- Q2 2018 pre announcement aide memoire PDF - 742.2KB
-
2012 First Quarter - released 25 April 2012
Watch Simon Dingemans, CFO, discuss our first quarter results 2012.
Key highlights
- Sales growth of +2% CER
- Further R&D delivery, operational leverage and continued returns to shareholders
- Core EPS 27.3p (+7%), dividend up 6% to 17p
-
2011 Fourth Quarter - released 07 February 2012
Sir Andrew Witty, CEO, discusses our fourth quarter results 2011.
Key highlights
- 2011 underlying sales +4% (reported -3%)
- EPS before major restructuring* 114.1p
- Total dividends of 75p
Related downloads
- Q4 2011 results announcement PDF - 331.1KB
- Q4 2011 Andrew Witty video transcript PDF - 104.1KB
- Q4 2011 Simon Dingemans video transcript PDF - 27.7KB
- Q4 2011 analyst presentation PDF - 1.8MB
- Q4 2011 restated quarterly product analysis PDF - 96.8KB
- Q4 2011 actual growth schedules PDF - 47.4KB
- Q4 2011 US dollar translation PDF - 45.1KB
-
2011 Third Quarter - released 26 October 2011
Simon Dingemans, CFO, discusses our third quarter results 2011.
Key highlights
- Underlying sales growth of 6% and reported sales growth of 3%
- EPS before major restructuring 28.5p, dividend 17p (up 6%)
- Strong contribution from Japan: sales +57%
-
2011 Second Quarter - released 26 July 2011
Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our second quarter results 2011.
Key highlights
- Q2 reported sales -2%
- EPS before major restructuring* 25p
- Underlying sales growth of 5%
- Increased pipeline visibility and dividend of 16p, up 7%
Other key information
-
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
-
Press releases
Keep up to date with our news and recent announcements
-
Product pipeline
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III
